![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 300, Issue 3, 1085-1092, March 2002
Laboratory of Neuropsychopharmacology, Department of Psychiatry and
Behavioral Sciences, Emory University School of Medicine, Atlanta,
Georgia
In a series of experiments, we tested the hypothesis that chronic
antidepressant drug administration reduces the synaptic availability of
corticotropin-releasing factor (CRF) through one or more effects on CRF
gene expression or peptide synthesis. We also determined whether
effects of acute or chronic stress on CRF gene expression or peptide
concentration are influenced by antidepressant drug treatment.
Four-week treatment with venlafaxine, a dual serotonin
(5-HT)/norepinephrine (NE) reuptake inhibitor, and tranylcypromine, a
monoamine oxidase inhibitor, resulted in an attenuation of acute
stress-induced increases in CRF heteronuclear RNA (hnRNA) synthesis in
the paraventricular nucleus (PVN). Trends toward the same effect were
observed after treatment with the 5-HT reuptake inhibitor fluoxetine,
or the NE reuptake inhibitor reboxetine. CRF mRNA accumulation in the
PVN during exposure to chronic variable stress was attenuated by
concurrent antidepressant administration. Basal CRF hnRNA and mRNA
expression were not affected by antidepressant treatment in the PVN or
in other brain regions examined. Chronic stress reduced CRF
concentrations in the median eminence, but there were no
consistent effects of antidepressant drug treatment on CRF, serum
corticotropin, or corticosterone concentrations. CRF receptor
expression and basal and stress-stimulated HPA axis activity were
unchanged after antidepressant administration. These results suggest
that chronic antidepressant administration diminishes the sensitivity
of CRF neurons to stress rather than alters their basal activity.
Additional studies are required to elucidate the functional
consequences and mechanisms of this interaction.
This article has been cited by other articles:
![]() |
M. R. Levy Cancer Fatigue: A Neurobiological Review for Psychiatrists Psychosomatics, July 1, 2008; 49(4): 283 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kier, J. Han, and L. Jacobson Chronic Treatment with the Monoamine Oxidase Inhibitor Phenelzine Increases Hypothalamic-Pituitary-Adrenocortical Activity in Male C57BL/6 Mice: Relevance to Atypical Depression Endocrinology, March 1, 2005; 146(3): 1338 - 1347. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Liu, B. Yu, L. Orozco-Cabal, D. E. Grigoriadis, J. Rivier, W. W. Vale, P. Shinnick-Gallagher, and J. P. Gallagher Chronic Cocaine Administration Switches Corticotropin-Releasing Factor2 Receptor-Mediated Depression to Facilitation of Glutamatergic Transmission in the Lateral Septum J. Neurosci., January 19, 2005; 25(3): 577 - 583. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hori, N. Yuyama, and K. Tamura Biting Suppresses Stress-induced Expression of Corticotropin-releasing Factor (CRF) in the Rat Hypothalamus Journal of Dental Research, February 1, 2004; 83(2): 124 - 128. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Shumake and F. Gonzalez-Lima Brain Systems Underlying Susceptibility to Helplessness and Depression Behav Cogn Neurosci Rev, September 1, 2003; 2(3): 198 - 221. [Abstract] [PDF] |
||||
![]() |
M. B. Stein A 46-Year-Old Man With Anxiety and Nightmares After a Motor Vehicle Collision JAMA, September 25, 2002; 288(12): 1513 - 1521. [Full Text] [PDF] |
||||